EMAIL THIS PAGE TO A FRIEND

Cardiovascular research

Liver X receptor activation enhances CVB3 viral replication during myocarditis by stimulating lipogenesis.


PMID 25998987

Abstract

Viral myocarditis (VM) is severe cardiac inflammation that can result in sudden death or congestive heart failure in previously healthy adults, with no effective therapy. Liver X receptor (LXR) agonists have both anti-inflammatory and lipid-lowering properties. This study investigates whether LXR agonist T0901317 may modulate viral replication and cardiac inflammation during VM. (i) Adult mice were administered T0901317 or vehicle with the onset of inflammation during CVB3 virus myocarditis or (ii) treated 2 days prior to CVB3 infection. Against what we expected, T0901317 treatment did not alter leucocyte infiltration after CVB3 infection; yet pre-administration with T0901317 resulted in increased mortality upon CVB3 infection, higher cardiac viral presence, and increased cardiomyocyte damage when compared with the vehicle. Furthermore, we show a correlation of fatty acid synthase (FAS) and sterol regulatory element-binding protein 1c (SREBP-1c) with CVB3 viral load in the heart and that T0901317 is able to enhance the cardiac expression of FAS and SREBP-1c. Finally, we show in vitro that T0901317 is able to exaggerate CVB3-mediated damage of Vero cells, whereas inhibitors of FAS and the SREBP-1c reduce the viral presence of CVB3 in neonatal cardiomyocytes. LXR agonism does not modulate cardiac inflammation, but exacerbates virus-mediated myocardial damage during VM by stimulating lipid biosynthesis and enhancing CVB3 replication.

Related Materials

Product #

Image

Description

Molecular Formula

Add to Cart

H1015
25-Hydroxycholesterol, ≥98%
C27H46O2
L5044
Anti-LXRα (N-terminal) antibody produced in rabbit, ~1.5 mg/mL, affinity isolated antibody, buffered aqueous solution
L5169
Anti-LXRβ (C-terminal) antibody produced in rabbit, IgG fraction of antiserum, buffered aqueous solution
AV38906
Anti-NR1H2 (AB1) antibody produced in rabbit, IgG fraction of antiserum
AV45633
Anti-NR1H2 (AB2) antibody produced in rabbit, IgG fraction of antiserum
SAB1412663
ANTI-NR1H2 antibody produced in mouse, clone 1B6, purified immunoglobulin, buffered aqueous solution
SAB2103395
Anti-NR1H2 antibody produced in rabbit, affinity isolated antibody
HPA056838
Anti-NR1H2 antibody produced in rabbit, Prestige Antibodies® Powered by Atlas Antibodies, affinity isolated antibody, buffered aqueous glycerol solution
SAB1406923
Anti-NR1H3 antibody produced in mouse, purified immunoglobulin, buffered aqueous solution
AV38670
Anti-NR1H3 antibody produced in rabbit, affinity isolated antibody
AV38669
Anti-NR1H3 antibody produced in rabbit, IgG fraction of antiserum
HPA036443
Anti-NR1H3 antibody produced in rabbit, Prestige Antibodies® Powered by Atlas Antibodies, affinity isolated antibody, buffered aqueous glycerol solution
SAB2106276
Anti-NR1H3 antibody produced in rabbit, affinity isolated antibody, lyophilized powder
C5490
C75, ≥98% (HPLC), powder
C14H22O4
WH0007376M1
Monoclonal Anti-NR1H2 antibody produced in mouse, clone 2H2-H3, purified immunoglobulin, buffered aqueous solution
SAB1404516
Monoclonal Anti-NR1H2 antibody produced in mouse, clone 1E1, purified immunoglobulin, buffered aqueous solution
SAB1402495
Monoclonal Anti-NR1H3 antibody produced in mouse, clone 3E9, purified immunoglobulin, buffered aqueous solution